Angiogenesis Inhibitors
"Angiogenesis Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.
Descriptor ID |
D020533
|
MeSH Number(s) |
D27.505.696.377.077.099 D27.505.696.377.450.100 D27.505.954.248.025
|
Concept/Terms |
Angiogenesis Inhibitors- Angiogenesis Inhibitors
- Neovascularization Inhibitors
- Angiogenic Antagonists
- Angiogenic Inhibitors
- Angiostatic Agents
- Agents, Angiostatic
- Antagonists, Angiogenic
- Anti-Angiogenetic Agents
- Agents, Anti-Angiogenetic
- Anti Angiogenetic Agents
- Anti-Angiogenic Drugs
- Anti Angiogenic Drugs
- Drugs, Anti-Angiogenic
- Antiangiogenic Agents
- Agents, Antiangiogenic
- Inhibitors, Angiogenesis
- Inhibitors, Angiogenetic
- Inhibitors, Angiogenic
- Inhibitors, Neovascularization
- Angiogenetic Antagonists
- Antagonists, Angiogenetic
- Angiogenetic Inhibitors
Anti-Angiogenesis Effect- Anti-Angiogenesis Effect
- Anti Angiogenesis Effect
- Effect, Anti-Angiogenesis
- Antiangiogenesis Effect
- Effect, Antiangiogenesis
- Antiangiogenesis Effects
- Effects, Antiangiogenesis
- Anti-Angiogenesis Effects
- Anti Angiogenesis Effects
- Effects, Anti-Angiogenesis
|
Below are MeSH descriptors whose meaning is more general than "Angiogenesis Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Angiogenesis Inhibitors".
This graph shows the total number of publications written about "Angiogenesis Inhibitors" by people in this website by year, and whether "Angiogenesis Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2001 | 0 | 1 | 1 | 2003 | 0 | 3 | 3 | 2006 | 2 | 1 | 3 | 2007 | 1 | 0 | 1 | 2008 | 2 | 0 | 2 | 2009 | 1 | 0 | 1 | 2010 | 1 | 0 | 1 | 2011 | 1 | 1 | 2 | 2012 | 2 | 0 | 2 | 2013 | 2 | 2 | 4 | 2015 | 4 | 0 | 4 | 2016 | 3 | 2 | 5 | 2017 | 1 | 0 | 1 | 2018 | 1 | 1 | 2 | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiogenesis Inhibitors" by people in Profiles.
-
Raghuram K, Isaac M, Yang J, AlAli A, Mireskandari K, Ly LG, Kelly E, Banihani R, Shah PS, Tehrani N. Neurodevelopmental outcomes in infants treated with intravitreal bevacizumab versus laser. J Perinatol. 2019 09; 39(9):1300-1308.
-
Khalili S, Shifrin Y, Pan J, Belik J, Mireskandari K. The effect of a single anti-Vascular Endothelial Growth Factor injection on neonatal growth and organ development: In-vivo study. Exp Eye Res. 2018 04; 169:54-59.
-
AlAli A, Bourgault S, Clark I, Lam WC. EXUDATIVE RETINAL DETACHMENT CAUSED BY A CHOROIDAL NEOVASCULAR MEMBRANE IN HALLERMANN-STREIFF SYNDROME. Retin Cases Brief Rep. 2018 Winter; 12(1):45-47.
-
Clark A, Wright T, Isaac M, Westall C, Mireskandari K, Tehrani NN. Macular morphology following unilateral bevacizumab injection for retinopathy of prematurity: an OCT study. J AAPOS. 2017 Dec; 21(6):499-501.e1.
-
Hammoud L, Adams JR, Loch AJ, Marcellus RC, Uehling DE, Aman A, Fladd C, McKee TD, Jo CEB, Al-Awar R, Egan SE, Rossant J. Identification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation Assay. Stem Cell Reports. 2016 10 11; 7(4):787-801.
-
Isaac M, Mireskandari K, Tehrani N. Does Bevacizumab Alter Vascularization Potential in Retinopathy of Prematurity? Ophthalmology. 2016 09; 123(9):2042-3.
-
Gana JC, Serrano CA, Ling SC. Angiogenesis and portal-systemic collaterals in portal hypertension. Ann Hepatol. 2016 May-Jun; 15(3):303-13.
-
Morin J, Luu TM, Superstein R, Ospina LH, Lefebvre F, Simard MN, Shah V, Shah PS, Kelly EN. Neurodevelopmental Outcomes Following Bevacizumab Injections for Retinopathy of Prematurity. Pediatrics. 2016 Apr; 137(4).
-
Isaac M, Tehrani N, Mireskandari K. Involution patterns of retinopathy of prematurity after treatment with intravitreal bevacizumab: implications for follow-up. Eye (Lond). 2016 Mar; 30(3):333-41.
-
Mireskandari K, Collins ME, Tehrani N. Intravitreal bevacizumab for retinopathy of prematurity: Considerations for informed consent. Can J Ophthalmol. 2015 Dec; 50(6):409-12.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|